What makes cancer stem cell markers different?

Since the cancer stem cell concept has been widely accepted, several strategies have been proposed to attack cancer stem cells (CSC). Accordingly, stem cell markers are now preferred therapeutic targets. However, the problem of tumor specificity has not disappeared but shifted to another question: h...

Descripción completa

Detalles Bibliográficos
Autores principales: Karsten, Uwe, Goletz, Steffen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3710573/
https://www.ncbi.nlm.nih.gov/pubmed/23888272
http://dx.doi.org/10.1186/2193-1801-2-301
_version_ 1782276885172977664
author Karsten, Uwe
Goletz, Steffen
author_facet Karsten, Uwe
Goletz, Steffen
author_sort Karsten, Uwe
collection PubMed
description Since the cancer stem cell concept has been widely accepted, several strategies have been proposed to attack cancer stem cells (CSC). Accordingly, stem cell markers are now preferred therapeutic targets. However, the problem of tumor specificity has not disappeared but shifted to another question: how can cancer stem cells be distinguished from normal stem cells, or more specifically, how do CSC markers differ from normal stem cell markers? A hypothesis is proposed which might help to solve this problem in at least a subgroup of stem cell markers. Glycosylation may provide the key.
format Online
Article
Text
id pubmed-3710573
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-37105732013-07-23 What makes cancer stem cell markers different? Karsten, Uwe Goletz, Steffen Springerplus Review Since the cancer stem cell concept has been widely accepted, several strategies have been proposed to attack cancer stem cells (CSC). Accordingly, stem cell markers are now preferred therapeutic targets. However, the problem of tumor specificity has not disappeared but shifted to another question: how can cancer stem cells be distinguished from normal stem cells, or more specifically, how do CSC markers differ from normal stem cell markers? A hypothesis is proposed which might help to solve this problem in at least a subgroup of stem cell markers. Glycosylation may provide the key. Springer International Publishing 2013-07-04 /pmc/articles/PMC3710573/ /pubmed/23888272 http://dx.doi.org/10.1186/2193-1801-2-301 Text en © Karsten and Goletz; licensee Springer. 2013 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Karsten, Uwe
Goletz, Steffen
What makes cancer stem cell markers different?
title What makes cancer stem cell markers different?
title_full What makes cancer stem cell markers different?
title_fullStr What makes cancer stem cell markers different?
title_full_unstemmed What makes cancer stem cell markers different?
title_short What makes cancer stem cell markers different?
title_sort what makes cancer stem cell markers different?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3710573/
https://www.ncbi.nlm.nih.gov/pubmed/23888272
http://dx.doi.org/10.1186/2193-1801-2-301
work_keys_str_mv AT karstenuwe whatmakescancerstemcellmarkersdifferent
AT goletzsteffen whatmakescancerstemcellmarkersdifferent

Ejemplares similares